A combination of apitherapy and plant extracts
Dietary SupplementThis combination contains the active comparator
NCT Number: NCT06756711
A pilot study to compare the efficacy of a combination of apitherapy supplements versus placebo in children with autistic spectrum disorder.
Interested in participating?
Request Info3 year–14 year
All sexes
Interventional
Not applicable
Clinica Aide Sante, Bucharest, Romania
A prospective, double-blind, placebo-controlled, crossover, multicentre clinical study which will enrol up to 45 children diagnosed with ASD (enrolment will stop when 40 children have completed the study). Children ages 3-14 will be tested before and after administering the combination of active substances (3 months) and placebo (3 months). The duration of participation in the study for each child will be 6 months. The supplements tested consist of three products - a combination of apitherapy and plant extracts - which have been approved for sale as individual supplements for more than 5 years in Romania - Apicol 12 gamma, Laptisor de matca activat (Royal Jelly) and Telom R Cerebral. Participation in the study is free and all children will be comparatively evaluated with the ATEC and ASRS scales and three sets of blood tests.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This combination contains the active comparator
A combination containing inert substances - placebo
Time frame: 3 months each of administration of active treatment and respectively placebo
Total ATEC (Autism Treatment Evaluation Checklist) scores before and after each intervention, as well subscale scores; higher scores indicate worse status, score range between 0 (minimal, absence of pathology), to 180 - maximal intensity of symptoms
Time frame: 3 months each of administration of active treatment and respectively placebo
Scores on Autism Spectrum Rating Scales (ASRS) tests, total and 8 subscales will be compared before and after each intervention; total scores vary between 50-255, with higher score indicating more severe symptoms
Time frame: 3 months each of administration of active treatment and respectively placebo
Changes in the levels of serum Neuron-specific enolase (NSE) will be compared between the two arms, higher levels indicate higher neuronal destruction
Time frame: 3 months each of administration of active treatment and respectively placebo
Adverse effects will be noted and compared for the two study arms
Fundatia Bio-Forum
Other
Acronym: APITSA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06604988
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD
Barcelona, Catalonia, Spain
View Trial DetailsNCT07243561
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD
Dongfang, Hainan, China
View Trial DetailsNCT07322952
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD
Chaozhou, Gaungdong, China
View Trial DetailsNCT07374081
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD
Bari, BA, Italy
View Trial Details